Q32 Bio Inc. — Filing identity and period
Important identity discrepancy: The supplied filing is Homology Medicines, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2018, filed November 13, 2018. It is not identified in the filing as Q32 Bio Inc.
Homology Medicines was a preclinical-stage genetic medicines company developing gene therapy and nuclease-free gene-editing treatments for rare diseases. It had no approved products and no product-sales revenue.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. The filing reports three- and nine-month results ended September 30.
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Collaboration revenue | $0.95 | — | $2.70 | — |
| Research and development | $13.39 | $4.95 | $31.67 | $11.80 |
| General and administrative | $3.84 | $1.72 | $12.21 | $5.59 |
| Total operating expenses | $17.24 | $6.66 | $43.88 | $17.39 |
| Operating loss | $(16.28) | $(6.66) | $(41.18) | $(17.39) |
| Interest income | $1.49 | $0.14 | $2.96 | $0.19 |
| Net loss | $(14.80) | $(6.53) | $(38.21) | $(18.09) |
| Basic and diluted loss per share | $(0.40) | $(2.78) | $(1.48) | $(7.43) |
At September 30, 2018, cash and cash equivalents were $36.0 million and short-term investments were $201.5 million, totaling $237.5 million. Current assets were $245.9 million and current liabilities $18.6 million; total assets were $268.4 million and total liabilities $55.6 million. The company reported no debt. Accumulated deficit was $78.4 million. No gross margin was reported; product-sales revenue had not begun.
Operating cash use was $34.5 million for the first nine months, compared with $15.6 million in 2017. Investing cash use was $132.0 million, primarily reflecting purchases of short-term investments and property and equipment. Financing provided $151.0 million, mainly from the IPO. Cash and cash equivalents alone fell to $36.0 million from $51.6 million at year-end 2017, while cash, cash equivalents and short-term investments rose to $237.5 million from $129.7 million. Management said existing resources were expected to fund operations and capital requirements for at least two years.
Changes versus the prior comparable period
- Nine-month operating expenses increased $26.5 million year over year, with R&D up $19.9 million and G&A up $6.6 million. Management attributed the increases principally to HMI-102 development and manufacturing costs, added personnel, research expenses, facilities and public-company costs.
- Nine-month net loss more than doubled to $38.2 million from $18.1 million. Higher interest income partly offset higher operating costs; the prior-year period also included a $0.9 million loss on a convertible preferred-stock tranche liability.
- The April 2018 IPO raised $150.8 million net. Preferred stock converted into common stock at the IPO closing; 37.3 million common shares were outstanding at September 30.
- Property and equipment, net, increased to $20.7 million from $3.2 million at year-end 2017, largely reflecting buildout of new research, manufacturing and office space.
Outlook, commentary and risks
- Management expected to initiate a Phase 1/2 trial of HMI-102 for phenylketonuria (PKU) and receive initial clinical data in 2019. It also expected to nominate gene-editing PKU and metachromatic leukodystrophy gene-therapy candidates by year-end 2018. These were forward-looking expectations, not reported achievements.
- The company expected operating expenses and capital spending to rise as it advanced programs, prepared for clinical trials, expanded manufacturing and operated as a public company. It estimated $22–$24 million of facility buildout and equipment capital expenditures through the first half of 2019, net of approximately $10.8 million in landlord reimbursement.
- The Novartis collaboration covered ophthalmic targets and sickle cell disease. The company had recognized $2.7 million of collaboration revenue in the first nine months and reported $33.3 million of deferred revenue at September 30. Potential payments included up to $960 million in development, regulatory and commercial milestones, plus tiered royalties; these amounts were contingent, not guaranteed revenue.
- The company remained dependent on additional capital beyond its estimated two-year runway and warned that financing might not be available on acceptable terms. Potential consequences included dilution, less favorable collaboration terms, or delaying or reducing development programs.
- Key disclosed risks included preclinical and clinical failure, gene-therapy safety and off-target effects, uncertain regulatory requirements, manufacturing capacity and supply, dependence on third parties, intellectual-property disputes, and the need to build internal manufacturing capabilities. The company noted reports of severe toxicity with very high doses of certain AAV vectors, while stating it had not observed those toxicities with its vectors to date.
- The company entered a sublease for its prior leased premises, with approximately $2.7 million of aggregate base rent expected from the subtenant. It reported no sublease loss. The new lease extends to 2027 and includes a tenant-improvement allowance of up to $10.9 million.
- Management concluded disclosure controls were effective at the reasonable-assurance level; no material changes in internal control over financial reporting were reported. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer: this source is Homology Medicines, Inc., despite the request metadata naming Q32 Bio Inc.
- Check subsequent filings and company announcements for whether the HMI-102 clinical-trial and candidate-nomination timelines were met.
- Assess cash burn, investment balances and capital needs against management’s stated minimum two-year runway, including actual facility spending and landlord reimbursements.
- Review Novartis collaboration performance, deferred-revenue recognition, milestone conditions, termination provisions and any later changes in the relationship.
- Track clinical, regulatory and manufacturing developments, including safety findings, CMC readiness and reliance on contract manufacturers.